Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997893 · ClinicalTrials.gov registry record · Phase 2
Research Investigation of Soy and Estrogen
A Phase 2 study of Menopause and Hot Flashes, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT00997893: Completed Phase 2 study of Menopause and Hot Flashes, sponsored by University of Illinois at Chicago.
NCT00997893 is a Phase 2 study of Menopause and Hot Flashes that has completed, run by University of Illinois at Chicago. The registered enrollment target is 96 participants, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00997893, a Phase 2 study of Menopause and Hot Flashes, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.
Primary Outcome
STAI-6; State-Trait Anxiety Inventory- Short Form is a measure of anxiety where higher scores indicate higher/elevated anxiety. Minimum value 6 is and maximum value is 24.
Conditions Studied
Interventions
- DRUG Estradiol
- DIETARY_SUPPLEMENT Soy Phytoestrogen
- DRUG Medroxyprogesterone Acetate (MPA)
- DRUG Soy Placebo
- DRUG MPA Placebo
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
What the finished NCT00997893 record still lists
NCT00997893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 9,392-participant average among 54 other Menopause trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Menopause appearing as the primary indexed condition, and to 5 interventions - of which Estradiol is the first listed.
NCT00997893 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00997893 about?
NCT00997893 is a clinical study titled "Research Investigation of Soy and Estrogen". The purpose of this study is to determine the effects of oral estradiol and soy phytoestrogens on anxiety, stress responsivity and cognition in perimenopausal women.
What is the current status of trial NCT00997893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2009-12. Estimated completion is 2015-05.
What conditions does trial NCT00997893 study?
This clinical trial studies the following conditions: Menopause, Hot Flashes.
What interventions are being tested in trial NCT00997893?
The interventions under investigation include: Estradiol (DRUG), Soy Phytoestrogen (DIETARY_SUPPLEMENT), Medroxyprogesterone Acetate (MPA) (DRUG), Soy Placebo (DRUG), MPA Placebo (DRUG).
Who is sponsoring clinical trial NCT00997893?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00997893 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00997893's enrollment target sits among peer trials
96 23rd of 54 higher than 32 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
Impact of Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia